An anticonvulsant
Related Products
Labeled Version(s)
30759Ethosuximide-d5
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Ethosuximide

Item No. 23947

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
3-ethyl-3-methyl-2,5-pyrrolidinedione
CAS Number
77-67-8
Synonyms
  • CI-366
  • NSC 64013
Molecular Formula
C7H11NO2
Formula Weight
141.2
Purity
≥95%
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
Methanol: Soluble
SMILES
O=C1CC(CC)(C)C(N1)=O
InChi Code
InChI=1S/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10)
InChi Key
HAPOVYFOVVWLRS-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    500 mg

    $46

    Add

    1 g

    $86

    Add
    Product Description

    Ethosuximide is an anticonvulsant.1,2,3,4,5 It increases glucose, fructose-1,6-bisphosphate, and pyruvate levels in rat brain when administered at a dose of 200 mg/kg.1 Ethosuximide (400 mg/kg) reduces the severity of audiogenic seizures in a rat model of barbiturate withdrawal-induced convulsions.2 It also inhibits tonic hindlimb extension induced by pentylenetetrazole (PTZ; Item No. 18682) or brainstem stimulation (ED50s = 35 and 70 mg/kg, respectively), as well as leptazol-induced clonic seizures (ED50 = 230 mg/kg), in rats.3,4 Ethosuximide reduces resting tremor by 60% in a macaque model of Parkinson's disease induced by MPTP when administered at a dose of 150 mg/animal for 5 days.5 Formulations containing ethosuximide have been used in the treatment of petit mal seizures.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Nahorski, S.R. Biochemical effects of the anticonvulsants trimethadione, ethosuximide and chlordiazepoxide in rat brain. J. Neurochem. 19(8), 1937-1946 (1972).

    2. Norton, P.R. The effects of drugs on barbiturate withdrawal convulsions in the rat. J. Pharm. Pharmacol. 22(10), 763-766 (1970).

    3. Consroe, P.F., and Wolkin, A.L. Anticonvulsant interaction of cannabidiol and ethosuximide in rats. J. Pharm. Pharmacol. 29(8), 500-501 (1977).

    4. Chiu, P., and Burnham, W.M. The effect of anticonvulsant drugs on convulsions triggered by direct stimulation of the brainstem. Neuropharmacology 21(4), 355-359 (1982).

    5. Gomez-Mancilla, B., Latulippe, J.F., Boucher, R., et al. Effect of ethosuximide on rest tremor in the MPTP monkey model. Mov. Disord. 7(2), 137-141 (1992).